Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: Pooled analysis of two long-term, randomized, follow-up studies

Epilepsia

Volumn 47, Issue 7, 2006, Pages 1121-1127

  Äikiä, Marja ^a   Jutila, Leena ^a   Salmenperä, Tuuli ^a   Mervaala, Esa ^a,b   Kälviäinen, Reetta ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antiepileptic drug; Cognition; Epilepsy; Monotherapy; Partial seizures

Indexed keywords

CARBAMAZEPINE; TIAGABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SEIZURE; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NIPECOTIC ACIDS;

EID: 33746179120     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00545.x     Document Type: Article

References (40)

1. Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003;4(suppl 2):S25-S38.
2. Dodrill CB. Neuropsychological effects of seizures. Epilepsy Behav 2004;5(suppl 1):S21-S24.
3. Rhea R. New oral antiepileptic agents. Cleve Clin Med Ed 2001;4. Available at http://clevelandclinicmeded.com/ medical_info/pharmacy/novdec2001/ antiepileptic.htm. Accessed March 17, 2006.
4. Weatherly G, Carlson BE, Risse GL, et al. Cognitive task performance of patients taking zonisamide: the Minnesota Epilepsy Group. 2003. Available at: http://www.mnepilepsy. org/PDFs/Weatherly_AES_2003.pdf.
5. Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient's perspective II: views about therapy and health care. Epilepsy Res 2000;41:53-61.
6. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3:618-621.
7. Fink-Jensen A, Suzdak PD, Swedberg MDB, et al. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
8. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996;29:335-356.
9. Leach JP, Brodie MJ. Tiagabine. Lancet 1998;351:203-207.
10. Crawford P, Meinardi H, Brown S, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia 2001;42:531-538.
11. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
12. Kälviäinen R, Brodie MJ, Duncan J, et al. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures: Northern European Tiagabine Study Group. Epilepsy Res 1998;30:31-40.
13. Sachdeo RC, Leroy RF, Krauss GJ, et al. Tiagabine therapy for complex partial seizures, a dose-frequency study, the tiagabine study group. Arch Neurol 1997;54:595-601.
14. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
15. Sveinbjornsdottir S, Sander JW, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:29-35.
16. Kälviäinen R, Äikiä M, Mervaala E, et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996;25:291-297.
17. Dodrill CB, Arnett JL, Sommerville KW, et al. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-1031.
18. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-381.
19. Dodrill CB, Arnett JL, Deaton R, et al. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 2000;42:123-132.
20. Äikiä M, Kälviäinen R, Salmenperä T, et al. Cognitive effects of tiagabine monotherapy. Epilepsia 1997;38:107.
21. Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:33-42.
22. Engelberts NH, Klein M, van der Ploeg HM, et al. Cognition and health-related quality of life in chronic well-controlled patients with partial epilepsy on carbamazepine monotherapy. Epilepsy Behav 2002;3:316-321.
23. Prevey ML, Delaney RC, Cramer JA, et al. Effects of valproate on cognitive functioning, comparison with carbamazepine. the Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996;53:1008-1016.
24. Drane DL, Meador KJ. Epilepsy, anticonvulsant drugs and cognition. Baillieres Clin Neurol 1996;5:877-885.
25. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995;36(suppl 2):S46-S65.
26. Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001;42(suppl 3):42-45.
27. Wechsler D. Wechsler Adult Intelligence Scale - Revised. San Antonio, Texas: The Psychological Corporation, 1981.
28. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press, 1995.
29. Wechsler DA. A standardized memory scale for clinical use. J Psychol 1945;19:87-95.
30. Reitan RM. The validity of the Trail-Making Test as an indicator of organic brain damage. Percept Mot Skill 1958;8:271-276.
31. Allison RS. Perseveration as a sign of diffuse and focal brain damage. BMJ 1966;2:1027-1032.
32. Alpherts WCJ, Aldenkamp AJ. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990;31:S35-S40.
33. Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive and behavioral effects of carbamazepine and phenytoin in healthy adults. Neurology 1991;41:1537-1540.
34. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001;56:1177-1182.
35. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40:1279-1285.
36. Imperiale TF. Meta-analysis: when and how. Hepatology 1999;29:26S-31S.
37. Ioannidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. Jt Comm J Qual Improv 1999;25:462-469.
38. Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin versus carbamazepine monotherapy in newly diagnosed epilepsy, a randomized controlled study. Arch Neurol 1995;52:989-996.
39. Dikmen SS, Heaton RK, Grant I, et al. Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc 1999;5:346-356.
40. Kälviäinen R. Cognitive effects of GABAergic antiepileptic drugs. Electroencephalogr Clin Neurophysiol 1999;50:458-464.